Building resilience in pharmaceutical supply chains

Rubrik: Fachthemen

(Treffer aus pharmind, Nr. 06, Seite 764 (2021))

Francas D

Building resilience in pharmaceutical supply chains / Strategies and analytics for risk management · Francas D · Heilbronn University and Healthcare Supply Chain Institute, Heilbronn
Over the past two decades, an increasing number of drug shortages have been reported [ 1 , 2 , 3 ]. The consolidation of production sites and the relocation of production to Asia have shaped the design of global supply chains [ 4 , 5 ]. While these adoptions helped to lower supply chain costs, they may have reduced the ability to withstand disruptions [ 6 ]. These past developments and today’s COVID-19 era have increased Pharma leaders’ focus on risk management considerably [ 7 ]. For example, Novartis states their “success depends on [the] ability to manage risk”  [ 8 ]. Likewise, Roche ...

Supply Chain Planning for Biopharmaceuticals

Rubrik: Fachthemen

(Treffer aus pharmind, Nr. 07, Seite 908 (2018))

Francas D

Supply Chain Planning for Biopharmaceuticals / How to Avoid Inventory Obsolescence · Francas D · Heilbronn University, Heilbronn
Figures from the US market show that drug expiration is indeed a significant issue. In 2007, the value of expired drugs was estimated to fall between 2.6 and 4.2 US dollars [ 1 ]. The growing share of biologics is putting additional pressure on supply chain management since these and other specialty products generally have shorter shelf lives. Misaligned inventory policies across the supply chain are a key root cause for drug expiration. Figure 1 illustrates how shelf life constraints affect the magnitude of replenishment lot sizes for warehouses and affiliates. In most pharma supply chains, such lot sizes are driven ...

Supply Chain Management

Rubrik: Fachthemen

(Treffer aus pharmind, Nr. 09, Seite 1270 (2016))

Francas D | Müßig R | Gmür A

Supply Chain Management / Part 2: Creating value with regional logistics hubs * Part 1 see Pharm Ind. 2015;77(10):1452–1457. · Francas D, Müßig R, Gmür A · ¹Camelot Management Consultants AG, Mannheim und ²Camelot Management Consultants AG, Basel, Switzerland
The world pharmaceutical market was worth an estimated 865 billion U.S. dollars at ex-factory prices in 2014, whereas the North American market (USA and Canada) remained the world’s largest market with a 44.5  % share, followed by Europe (25.3  % share) and Japan (8.9  % share). However, the growth rates in emerging economies such as Brazil, China and India far exceed the rates in mature markets [ 1 , 2 ]. The predominant distribution model for pharma companies is to rely on dispersed—and mostly historically grown—distribution networks with one or several local distribution centers (DCs) in each market. For instance, rather than using ...